Table 1. Baseline characteristics.
| Category | Subcategory | All patients (5982 [100%]) | TB cases (N = 336 [5.6%]) | Non-TB cases (N = 5646 [94.3%]) |
| Sex (female) | 3978 (66.5) | 185 (55.1) | 3793 (67.2) | |
| Age (years, mean [SD]) | 37.2 (8.7) | 36.9 (8.7) | 37.2 (8.7) | |
| WHO stage a | I&II | 2210 (37.1) | 98 (29.2) | 2112 (37.6) |
| III | 2367 (39.7) | 145 (43.2) | 2222 (39.5) | |
| IV | 1380 (23.2) | 93 (27.7) | 1287 (22.9) | |
| Baseline CD4 count a (cells/mm3, median [IQR]) | 117 (42, 182) | 85.5 (31.5, 153.5) | 119 (43, 183) | |
| Baseline CD4 count a (cells/mm3) | ≥200 | 988 (17.3) | 36 (11.3) | 952 (17.7) |
| 50–199 | 3140 (55.1) | 172 (53.8) | 2968 (55.2) | |
| <50 | 1572 (27.6) | 112 (35.0) | 1460 (27.1) | |
| Baseline CD4 percentage a (median [IQR]) | 7.0 (3.3, 11.4) | 6.0 (3.0, 9.0) | 7.0 (3.4, 11.8) | |
| ART regimen | d4T+3TC+NVP | 3205 (53.6) | 215 (64.0) | 2990 (53.0) |
| d4T+3TC+EFV | 75 (1.3) | 9 (2.7) | 66 (1.2) | |
| AZT+3TC+NVP | 351 (5.9) | 11 (3.3) | 340 (6.0) | |
| AZT+3TC+EFV | 2159 (36.1) | 94 (28.0) | 2065 (36.6) | |
| Other 1st line b | 192 (3.2) | 7 (2.1) | 185 (3.3) |
TB, tuberculosis; ART, antiretroviral therapy; IQR, interquartile range; d4T, stavudine; 3TC, lamivudine; NVP, nevirapine; AZT, zidovudine; EFV, efavirenz.
a
Data on CD4 count and CD4 percentage were not available for 282 patients (16 with incident TB); CD4 counts and percentages were closest recorded values to the baseline start date, maximum 6 months pre and 15 days post ART initiation. Data on WHO stage were not available for 25 patients.
b
Other first line triple ART regimens.